Twist Bioscience Corporation $TWST Shares Purchased by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 186.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,442,262 shares of the company’s stock after purchasing an additional 1,588,587 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 4.08% of Twist Bioscience worth $95,883,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock valued at $27,000 after acquiring an additional 580 shares during the period. GAMMA Investing LLC increased its position in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after buying an additional 303 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Twist Bioscience in the fourth quarter valued at $58,000. Bayforest Capital Ltd increased its position in shares of Twist Bioscience by 49.3% in the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock valued at $191,000 after buying an additional 1,604 shares in the last quarter. Finally, Pallas Capital Advisors LLC purchased a new position in shares of Twist Bioscience in the first quarter valued at $201,000.

Analyst Ratings Changes

A number of research analysts have recently weighed in on TWST shares. Cowen restated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Evercore ISI set a $46.00 price objective on Twist Bioscience in a research report on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $49.40.

Twist Bioscience Stock Down 1.2%

TWST opened at $25.31 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -17.46 and a beta of 2.31. The business has a 50-day moving average of $30.52 and a two-hundred day moving average of $34.21. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The company had revenue of $96.06 million during the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other news, CEO Emily M. Leproust sold 2,265 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $25.76, for a total transaction of $58,346.40. Following the completion of the sale, the chief executive officer owned 634,740 shares in the company, valued at approximately $16,350,902.40. The trade was a 0.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Laponis sold 2,449 shares of the business’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the sale, the chief financial officer owned 103,569 shares of the company’s stock, valued at $3,951,157.35. The trade was a 2.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 8,911 shares of company stock valued at $288,159 in the last quarter. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.